Table 2. Demographic Data and Psychophysiological Parameters of German Schizophrenia Patients.
| CHRNA3 rs1051730 genotype | TT | TC | CC | Total | F/χ2 | df/dferr | p | ηp2 |
|---|---|---|---|---|---|---|---|---|
| CHRNA3 rs1317286 genotype | GG | GA | AA | |||||
| N | 9 (13.2%) | 31 (45.6%) | 28 (41.2%) | 68 (100%) | ||||
| Age (years) | 35.3 (2.5) | 33.8 (1.6) | 35.5 (2.4) | 34.7 (1.3) | 0.20 | 2/67 | 0.81 | 0.01 |
| Years of education | 15.1 (0.8) | 14.8 (0.5) | 13.9 (0.7) | 14.5 (0.3) | 0.86 | 2/67 | 0.43 | 0.03 |
| Men (%) | 77.8 | 71.0 | 64.3 | 69.1 | 0.67 | 2 | 0.72 | — |
| Current smokers (%) | 22.2 | 54.8 | 64.3 | 54.4 | 4.86 | 2 | 0.09 | — |
| Patients with a first-episode (%) | 33.3 | 71.0 | 64.3 | 63.2 | 4.27 | 2 | 0.12 | — |
| Age of onset (years) | 28.2 (2.5) | 31.4 (1.7) | 30.1 (2.0) | 30.4 (1.2) | 0.40 | 2/67 | 0.68 | 0.01 |
| Duration of illness (years) | 7.1 (3.0) | 2.5 (0.9) | 5.8 (2.0) | 4.5 (1.0) | 1.76 | 2/67 | 0.18 | 0.05 |
| Number of episodes | 3.3 (0.9) | 1.6 (0.2) | 2.1 (0.4) | 2.0 (0.2) | 3.81 | 2/67 | 0.03a | 0.11 |
| Medication status (%) (unmedicated/typical/atypical antipsychotic drug) | 0/22/78 | 16/16/68 | 32/18/50 | 21/18/62 | 5.30 | 4 | 0.26 | — |
| Daily chlorpromazine equivalentsb | 463 (68.0) | 246 (32.2) | 228.8 (42.8) | 266 (26.0) | 4.67 | 2/67 | 0.01c | 0.14 |
| PANSS positive | 18.7 (2.3) | 19.1 (1.5) | 17.3 (1.4) | 18.3 (0.9) | 0.42 | 2/67 | 0.66 | 0.01 |
| PANSS negative | 21.4 (1.6) | 23.0 (1.4) | 17.5 (1.4) | 20.5 (0.9) | 4.40 | 2/67 | 0.02d | 0.13 |
| PANSS general | 43.1 (4.8) | 43.1 (2.4) | 36.8 (2.5) | 40.5 (1.7) | 1.83 | 2/67 | 0.17 | 0.06 |
| PANSS total | 83.2 (8.1) | 85.6 (4.7) | 71.5 (4.9) | 79.5 (3.2) | 2.25 | 2/67 | 0.11 | 0.07 |
| First block, amplitude of pulse-alone trials (arbitrary units) | 280 (97.7) | 278 (27.6) | 248.5 (36.8) | 266 (23.1) | 0.20 | 2/67 | 0.82 | 0.01 |
| Mean amplitude of pulse-alone trials (arbitrary units) | 238 (89.9) | 221 (28.0) | 179.2 (29.2) | 206 (20.9) | 0.61 | 2/67 | 0.55 | 0.02 |
| Mean percent prepulse inhibitione (SOA: 120 ms) | 20.3% (9.8) | 50.6% (5.6) | 35.5% (2.3) | 41.9% (3.3) | 4.26 | 2/63 | 0.02f | 0.13 |
| Percent early habituation of pulse-alone trials (between first and second block) | 24.0% (9.2) | 23.4% (4.9) | 22.6% (5.1) | 23.2% (3.3) | 0.01 | 2/67 | 0.99 | 0.00 |
| Percent total habituation of pulse-alone trials (between first and sixth block) | 42.2% (10.7) | 37.3% (6.0) | 40.4% (5.5) | 39.3% (3.8) | 0.12 | 2/67 | 0.89 | 0.00 |
| Habituation of pulse-alone trials across six blocks (linear gradient coefficient b) | −13.6 (4.6) | −16.0 (3.5) | −17.8 (3.7) | −16.4 (2.3) | 0.18 | 2/67 | 0.84 | 0.01 |
CHRNA3 rs1051730 and rs1317286 polymorphisms were in complete linkage disequilibrium.
German schizophrenia patients grouped according to their CHRNA3 rs1051730 and rs1317286 genotype (mean±SEM values in parentheses, gender and smoking status in frequency data)
a
Bonferroni post hoc test: TT/GG>TC/GA, p<0.05.
b
Unmedicated patients received the value zero.
c
Bonferroni post hoc test: TT/GG>TC/GA & CC/AA, p<0.05.
d
Bonferroni post hoc test: CC/AA<TC/GA, p<0.05.
e
ANCOVA, means adjusted by covariates gender and smoking status.
f
Bonferroni post hoc test: TT/GG<TC/GA, p<0.05.